TY - JOUR
T1 - Arrhythmias in congenital heart disease
T2 - a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE
AU - Hernandez-Madrid, Antonio
AU - Paul, Thomas
AU - Abrams, Dominic
AU - Aziz, Peter F.
AU - Blom, Nico A.
AU - Chen, Jian
AU - Chessa, Massimo
AU - Combes, Nicolas
AU - Dagres, Nikolaos
AU - Diller, Gerhard
AU - Ernst, Sabine
AU - Giamberti, Alessandro
AU - Hebe, Joachim
AU - Janousek, Jan
AU - Kriebel, Thomas
AU - Moltedo, Jose
AU - Moreno, Javier
AU - Peinado, Rafael
AU - Pison, Laurent
AU - Rosenthal, Eric
AU - Skinner, Jonathan R.
AU - Zeppenfeld, Katja
AU - Sticherling, Christian
AU - Kautzner, Joseph
AU - Wissner, Erik
AU - Sommer, Philipp
AU - Gupta, Dhiraj
AU - Szili-Torok, Tamas
AU - Tateno, Shigeru
AU - Alfaro, Armando
AU - Budts, Werner
AU - Gallego, Pastora
AU - Schwerzmann, Markus
AU - Milanesi, Ornella
AU - Sarquella-Brugada, Georgia
AU - Kornyei, Laszlo
AU - Sreeram, Narayanswami
AU - Drago, Fabrizio
AU - Dubin, Anne
PY - 2018/11/1
Y1 - 2018/11/1
N2 - The population of patients with congenital heart disease (CHD) is continuously increasing with more and more patients reaching adulthood. A significant portion of these young adults will suffer from arrhythmias due to the underlying congenital heart defect itself or as a sequela of interventional or surgical treatment. The medical community will encounter an increasing challenge as even most of the individuals with complex congenital heart defects nowadays become young adults. Within the past 20 years, management of patients with arrhythmias has gained remarkable progress including pharmacological treatment, catheter ablation, and device therapy. Catheter ablation in patients with CHD has paralleled the advances of this technology in pediatric and adult patients with structurally normal hearts. Growing experience and introduction of new techniques like the 3D mapping systems into clinical practice have been particularly beneficial for this growing population of patients with abnormal cardiac anatomy and physiology. Finally, device therapies allowing maintanence of chronotropic competence and AV conduction, improving haemodynamics by cardiac resynchronization, and preventing sudden death are increasingly used. For pharmacological therapy, ablation procedures, and device therapy decision making requires a deep understanding of the individual pathological anatomy and physiology as well as detailed knowledge on natural history and long-term prognosis of our patients. Composing expert opinions from cardiology and paediatric cardiology as well as from non-invasive and invasive electrophysiology this position paper was designed to state the art in management of young individuals with congenital heart defects and arrhythmias.
AB - The population of patients with congenital heart disease (CHD) is continuously increasing with more and more patients reaching adulthood. A significant portion of these young adults will suffer from arrhythmias due to the underlying congenital heart defect itself or as a sequela of interventional or surgical treatment. The medical community will encounter an increasing challenge as even most of the individuals with complex congenital heart defects nowadays become young adults. Within the past 20 years, management of patients with arrhythmias has gained remarkable progress including pharmacological treatment, catheter ablation, and device therapy. Catheter ablation in patients with CHD has paralleled the advances of this technology in pediatric and adult patients with structurally normal hearts. Growing experience and introduction of new techniques like the 3D mapping systems into clinical practice have been particularly beneficial for this growing population of patients with abnormal cardiac anatomy and physiology. Finally, device therapies allowing maintanence of chronotropic competence and AV conduction, improving haemodynamics by cardiac resynchronization, and preventing sudden death are increasingly used. For pharmacological therapy, ablation procedures, and device therapy decision making requires a deep understanding of the individual pathological anatomy and physiology as well as detailed knowledge on natural history and long-term prognosis of our patients. Composing expert opinions from cardiology and paediatric cardiology as well as from non-invasive and invasive electrophysiology this position paper was designed to state the art in management of young individuals with congenital heart defects and arrhythmias.
KW - Congenital heart disease
KW - Arrhythmia
KW - Sudden cardiac death
KW - Heart failure
KW - Macroreentry tachycardia
KW - Atrioventricular block
KW - Bradycardia
KW - Implantable cardioverter-defibrillator
KW - Pacemaker
KW - Cardiac resynchronization therapy
KW - Ablation
KW - European Heart Rhythm Association position paper
KW - CARDIAC-RESYNCHRONIZATION THERAPY
KW - IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
KW - RADIOFREQUENCY CATHETER ABLATION
KW - SINUS NODE DYSFUNCTION
KW - ATRIAL-SEPTAL-DEFECT
KW - INTRAATRIAL REENTRANT TACHYCARDIA
KW - LONG-TERM OUTCOMES
KW - ATRIOVENTRICULAR RECIPROCATING TACHYCARDIA
KW - LEFT-VENTRICULAR DYSFUNCTION
KW - ANTIARRHYTHMIC-DRUG-THERAPY
U2 - 10.1093/europace/eux380
DO - 10.1093/europace/eux380
M3 - Article
C2 - 29579186
SN - 1099-5129
VL - 20
SP - 1719
EP - 1753
JO - EP Europace
JF - EP Europace
IS - 11
ER -